Search Results

Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies with 2020 revenue of $17.5 billion, announced that it has entered into a definitive agreement through which it will receive a majority investment from a partnership comprised of funds managed by Blackstone, Carlyle and Hellman & Friedman.

Cardinal Health announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of certain working capital accounts.

Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.

NextRNA Therapeutics, a biotechnology company unlocking the potential of long non-coding RNAs (lncRNAs) to develop transformative medicines for multiple diseases with an initial focus on oncology and neurology, today announced the appointment of Lori Friedman, PhD, to its Board of Directors.

Barrow Neurological Institute at Phoenix Children’s, one of the largest pediatric neuroscience programs in the country, announced the appointment of Neil Friedman, MBChB as director.

Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.

Dr. Friedman brings 30 years of success in delivering value for patients, healthcare providers, and payors to help Transplant Genomics deliver on its mission.

This partnership will establish a new research and production facility in Andhra Pradesh, driving India’s transition toward pharmaceutical leadership and creating high-tech jobs

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, has been appointed to the company’s board of directors.